Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Recruiting No phase listed Observational

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

NCT07242963
View directory record Official record
Conditions
Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype
Interventions
Not listed
Lead sponsor
Mohammad H. Abu Arja
Other
Eligibility
3 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cardiovascular Disease Risk in Women With Endometriosis

NCT03746535
View directory record Official record
Conditions
Endometriosis
Interventions
Elagolix
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Not listed Not applicable Interventional

FIT-ATOMIC Exercise Feasibility Trial

NCT06870968
View directory record Official record
Conditions
Neuroinflammatory Diseases, Multiple Sclerosis
Interventions
Exercise Training, Mobility and Flexibility Training
Behavioral
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
11 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 23, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV

NCT06013579
View directory record Official record
Conditions
HIV Infections, Cognitive Impairment
Interventions
Phase 1 Gym Exercise HIIT, Phase 1 Gym Exercise CME, Phase 2 Home Exercise Coaching Text Messages, Phase 2 Home Exercise Control Text Messages
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 23, 2026, 8:29 AM EDT
Active, not recruiting Phase 2 Interventional

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

NCT02210078
View directory record Official record
Conditions
Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Iadademstat + SBRT With Atezo in ES-SCLC

NCT07113691
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Iadademstat, Atezolizumab, SBRT
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Progressive Resistance Training in Patients With Class III Obesity

NCT01100450
View directory record Official record
Conditions
Obesity
Interventions
Progressive Resistance Training
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 23, 2026, 8:29 AM EDT
Approved For Marketing No phase listed Expanded access

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

NCT00062660
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 23, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional

PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction

NCT05609097
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
PRIME, COMBO
Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Not applicable Interventional

Early Progressive Feeding in Human-Milk Fed Extremely Preterm Infants: A Randomized Trial

NCT02915549
View directory record Official record
Conditions
Premature; Infant, Light-for-dates
Interventions
Progressive Feeding without MEF, Progressive Feeding with MEF
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
24 Hours to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 23, 2026, 8:29 AM EDT
Suspended Phase 1 Interventional

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

NCT05887882
View directory record Official record
Conditions
Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Neoplasm
Interventions
Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells, Implantation, Magnetic Resonance Imaging (MRI), Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 38 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Recruiting Phase 4 Interventional

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

NCT01818661
View directory record Official record
Conditions
PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia, Primary Progressive Aphasia
Interventions
AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

NCT00381797
View directory record Official record
Conditions
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions
Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
Biological · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 23, 2026, 8:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Shear Wave Sonoelastography in Pediatric Liver Fibrosis

NCT02372682
View directory record Official record
Conditions
Sonoelastography, Elastography, Elastograms, Liver Fibrosis, Hepatic Fibrosis, Cirrhosis, Pediatrics
Interventions
Shear wave sonoelastography
Device
Lead sponsor
St. Louis University
Other
Eligibility
Up to 18 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Rehabilitation Programs for Patellofemoral Pain Syndrome

NCT00445224
View directory record Official record
Conditions
Patellofemoral Pain Syndrome
Interventions
Hip Progressive Resistive Exercise, Quad Progressive Resistive Exercises
Other
Lead sponsor
Timothy Uhl
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

NCT00006474
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, temozolomide, conventional surgery
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Not applicable Interventional Results available

RELAXaHEAD for Headache Patients (Phase II)

NCT05466682
View directory record Official record
Conditions
Migraine, Headache, Multiple Sclerosis, Insomnia
Interventions
Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 23, 2026, 8:29 AM EDT
Terminated Early Phase 1 Interventional

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

NCT04906382
View directory record Official record
Conditions
Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer
Interventions
Biopsy, Carboplatin, Paclitaxel, Tislelizumab
Procedure · Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 23, 2026, 8:29 AM EDT
Not yet recruiting Not applicable Interventional

Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial

NCT07606313
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Cancer, Functional Limitation
Interventions
Functional Resistance Training, Stretching, Delayed Functional Resistance Training
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Not listed Not applicable Interventional

Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures

NCT02777060
View directory record Official record
Conditions
Diabetes, Cancer, Multiple Sclerosis, Arthritis, Parkinson's Disease, Cognitive Disorders, Brain Injury, Stroke
Interventions
Exergame, Home based balance training
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 23, 2026, 8:29 AM EDT
Recruiting Not applicable Interventional

SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers

NCT07269262
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
SUPPORT-T Educational Intervention
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

NCT00047281
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
celecoxib, cyclophosphamide, etoposide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 23, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845
View directory record Official record
Conditions
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Interventions
G207
Biological
Lead sponsor
Gregory K. Friedman, MD
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 23, 2026, 8:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457
View directory record Official record
Conditions
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
Interventions
Dabrafenib, Trametinib, Hydroxychloroquine
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 30 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 8:29 AM EDT